Arrowhead scores bull's-eye with $45M private offering

RNAi biotech Arrowhead Pharmaceuticals ($ARWR) has sold off more than 7.6 million shares at just under $6 a pop, raising $45 million toward its R&D projects--including its work with Novartis’ ($NVS) assets.

The Californian biotech, formerly known as Arrowhead Research, said it had raised the cash through a series of investors, including that perennial life sciences Orbimed, as well as RA Capital Management, Perceptive Advisors, RTW Investments and others.

The company is working on developing gene silencing techniques, with a number of its RNAi assets bought from Novartis in a $35 million deal that saw it grab the rights to three preclinical candidates.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

In 2011, it bought out Roche’s ($RHHBY) RNAi platform as this tech moved out of Big Pharma and into smaller biotech.

Arrowhead has for some time been locked in a rivalry with fellow RNAi specialist Alnylam ($ALNY) to get their RNAi meds onto the market first.

It’s been a long time coming given that gene silencing as a concept garnered the Nobel prize a decade ago, but has lingered on the fringe of commercialization ever since then.

But there is much promise here as analysts have forecast that RNA-based therapies could generate $1.2 billion in revenue by the decade’s end.

Last year, Arrowhead also posted positive data for its hepatitis B virus candidate and is also currently working on treating the genetic disease alpha-1 antitrypsin deficiency.

- check out the release

Related Article:
Arrowhead acquires Novartis' RNAi assets, but Alnylam CEO calls them 'unuseful.' Who's right?

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.